A Dutch court ruled that Merck infringed Halozyme's MDASE patent EP622 and ordered Merck's affiliate MSD BV to stop manufacturing, selling, and importing Keytruda SC in several European countries. The injunction covers Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands, but patients can still access the intravenous version of Keytruda. This ruling is part of Halozyme's global legal efforts against Merck's subcutaneous Keytruda formulation, which Halozyme claims violates multiple patents. The case continues in other jurisdictions, including the U.S. and Germany.
Merck & Co., Inc. (MRK) shares are trading at USD 141.76 on Pluang, showing a slight decline of 0.12% as of Oct 07, 2026 19:43 WIB. The stock maintains a market cap of $350.19 billion with a dividend yield of 2.4%, while Pluang order activity leans 60% Buy and 40% Sell at this time.
